NASDAQ:HURA - Nasdaq - US8989201038 - Common Stock - Currency: USD
NASDAQ:HURA (2/21/2025, 8:26:15 PM)
3.33
+0.03 (+0.91%)
The current stock price of HURA is 3.33 USD. In the past month the price decreased by -27.92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
TuHURA Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The company went IPO on 2016-07-12. TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
TUHURA BIOSCIENCES INC
10500 University Center Dr., Suite 110
Tampa FLORIDA US
Employees: 1
Company Website: https://www.kintara.com/
Investor Relations: http://ir.kintara.com
Phone: 18138756600
The current stock price of HURA is 3.33 USD. The price increased by 0.91% in the last trading session.
The exchange symbol of TUHURA BIOSCIENCES INC is HURA and it is listed on the Nasdaq exchange.
HURA stock is listed on the Nasdaq exchange.
7 analysts have analysed HURA and the average price target is 12.37 USD. This implies a price increase of 271.4% is expected in the next year compared to the current price of 3.33. Check the TUHURA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 140.79M USD. This makes HURA a Micro Cap stock.
TUHURA BIOSCIENCES INC (HURA) currently has 1 employees.
TUHURA BIOSCIENCES INC (HURA) has a support level at 3.17 and a resistance level at 4.32. Check the full technical report for a detailed analysis of HURA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HURA does not pay a dividend.
TUHURA BIOSCIENCES INC (HURA) will report earnings on 2025-05-12.
TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.67).
The outstanding short interest for TUHURA BIOSCIENCES INC (HURA) is 3.94% of its float. Check the ownership tab for more information on the HURA short interest.
ChartMill assigns a technical rating of 1 / 10 to HURA.
ChartMill assigns a fundamental rating of 2 / 10 to HURA. HURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -4.67. The EPS increased by 40.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -182.13% | ||
ROE | -444.84% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to HURA. The Buy consensus is the average rating of analysts ratings from 7 analysts.